Clinical Trial Update: Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial examining Surovatamig (AZD0486) as monotherapy in relapsed/refractory B-cell non-Hodgkin lymphoma, including follicular lymphoma and di…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma

Drugs mentioned

• Surovatamig

Snippet

Sponsor: AstraZeneca | Conditions: B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL) | Phase 2 | Status: RECRUITING